Caris Life Sciences Launches $494M IPO to Advance AI-Driven Precision Medicine
- bancheta6
- Jul 2
- 1 min read
Irving, TX, June 17, 2025 (PRNewswire) -- Caris Life Sciences, a next-generation AI-driven TechBio and precision medicine pioneer, has priced its IPO at $21.00 per share, offering 23.5 million shares and granting underwriters a 30-day option to purchase an additional 3.5 million shares. The stock will trade on the Nasdaq Global Select Market under the ticker “CAI” beginning June 18, 2025, with the offering expected to close on June 20. BofA Securities, J.P. Morgan, and Goldman Sachs are leading the underwriting syndicate, joined by Citigroup and others. With its AI-enabled clinico-genomic platform, Caris is positioned to reshape healthcare through data-driven solutions for early detection, diagnosis, treatment, and drug development.
Read full article here.
Comentarios